New Investment Boosts Ophthalmic Gene Therapy Access in Hong Kong and Macau
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of advancements in gene therapy offers a beacon of hope. A recent significant investment by C-MER Medical in CHIGENOVO is poised to accelerate the availability of cutting-edge ophthalmic gene therapies in Hong Kong and Macau, potentially bringing new treatment options closer to those who need them most. This development highlights a growing commitment to addressing IRDs and improving vision outcomes in the region.
On May 21, 2026, C-MER Medical Holdings Limited announced its acquisition of a 10.23% stake in CHIGENOVO Co., Ltd., a company specializing in ophthalmic gene therapy. The investment, totaling RMB 112.63 million, signifies a strategic move to advance gene therapy for eye conditions. As part of this collaboration, C-MER Medical will secure exclusive rights to utilize CHIGENOVO's lead gene therapy, ZVS101e, in both Hong Kong and Macau. Furthermore, C-MER Medical will be designated as the exclusive treatment center and center of excellence for this therapy in Hong Kong.
CHIGENOVO, established in 2016, is a high-tech enterprise focused on gene therapy drug development and genetic diagnosis for inherited eye diseases. The company aims to provide